The estimated Net Worth of Mark J Casey is at least $7.53 Milhão dollars as of 12 May 2016. Mr. Casey owns over 34,450 units of Mallinckrodt Plc stock worth over $11,713 and over the last 17 years he sold MNK stock worth over $3,559,619. In addition, he makes $3,957,570 as Executive Vice President and Chief Legal Officer at Mallinckrodt Plc.
Mark has made over 13 trades of the Mallinckrodt Plc stock since 2010, according to the Form 4 filled with the SEC. Most recently he bought 34,450 units of MNK stock worth $49,608 on 12 May 2016.
The largest trade he's ever made was selling 129,526 units of Mallinckrodt Plc stock on 9 January 2013 worth over $2,854,753. On average, Mark trades about 5,810 units every 48 days since 2008. As of 12 May 2016 he still owns at least 34,450 units of Mallinckrodt Plc stock.
You can see the complete history of Mr. Casey stock trades at the bottom of the page.
Mark J. Casey serves as Executive Vice President and Chief Legal Officer of the Company. e joined Mallinckrodt in February 2018 as our General Counsel and has executive responsibility for all legal functions, including those related to litigation, intellectual property, environmental and regulatory matters, and mergers and acquisitions. Mr. Casey is also responsible for the Company's government affairs, policy and patient advocacy functions, as well as the Company's Specialty Generics business. Prior to joining Mallinckrodt, he served as Senior Vice President, General Counsel & Secretary of Idera Pharmaceuticals from June 2015 to January 2018. Mr. Casey also served as Senior Vice President, Chief Administrative Officer, General Counsel & Secretary of Hologic, Inc. ("Hologic") from March 2012 to December 2014, and as Senior Vice President, General Counsel & Secretary at Hologic from October 2007 to February 2012. Mr. Casey began his career as a patent attorney for the Digital Equipment Corporation and for EMC Corporation, and served as Senior Patent Counsel for two years at Boston Scientific, after which he progressed to Chief Patent Counsel and Deputy General Counsel for Cytyc Corporation.
As the Executive Vice President and Chief Legal Officer of Mallinckrodt Plc, the total compensation of Mark Casey at Mallinckrodt Plc is $3,957,570. There are 3 executives at Mallinckrodt Plc getting paid more, with Mark Trudeau having the highest compensation of $14,610,800.
Mark Casey is 56, he's been the Executive Vice President and Chief Legal Officer of Mallinckrodt Plc since 2019. There are 10 older and 2 younger executives at Mallinckrodt Plc. The oldest executive at Mallinckrodt Plc is J. Martin Carroll, 70, who is the Independent Director.
Mark's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over $29,853,069 worth of Mallinckrodt Plc stock and bought 2,559,592 units worth $174,429,961 . The most active insiders traders include & Co. Inc. Paulson, James E Deerfield Mgmt L.P...., eNancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of $10,061. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth $9,495.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: